Lexicon Pharmaceuticals (LXRX) Cash from Investing Activities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Cash from Investing Activities for 17 consecutive years, with -$70.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 273.14% year-over-year to -$70.3 million; the TTM figure through Mar 2026 stood at $2.2 million (down 98.39% YoY), while the FY2025 annual figure was $113.0 million, up 834.95% from the prior year.
• Cash from Investing Activities fell to -$70.3 million in Q1 2026 per LXRX's latest filing, from $4.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $53.7 million in Q4 2024 and bottomed at -$110.2 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$5.5 million across 5 years, with a median of $4.8 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 19199.0% — and 2023, when it surged 374.34%.
• Lexicon Pharmaceuticals' Cash from Investing Activities stood at $24.2 million in 2022, then jumped by 114.69% to $51.9 million in 2023, then climbed by 3.47% to $53.7 million in 2024, then tumbled by 91.01% to $4.8 million in 2025, then sank by 1554.72% to -$70.3 million in 2026.
• Business Quant data shows LXRX's Cash from Investing Activities at -$70.3 million in Q1 2026, $4.8 million in Q4 2025, and $52.1 million in Q3 2025.